Trending...
- Sycor Introduces Spring Release 2026 of Sycor.Rental with AI-Driven Innovations and Enhanced Service Processes
- Everwild Music Festival Unveils 2026 Schedule: No Overlapping Sets, Longer Performances, and Epic Late-Night Sets!
- MAG Magna Corp Targets Trillion-Dollar Opportunity by Tokenizing Rare Earth Assets Critical to AI, EVs, & Defense: MAG Magna Corp.: Stock Symbol: MGNC
GREENSBORO, N.C., Nov. 20, 2020 /PRNewswire/ -- Greensboro-based, Carolina Liquid Chemistries Corp. (CLC) has been tirelessly working since the beginning of the COVID-19 outbreak to provide high-quality testing kits and instruments to healthcare providers and laboratories as quickly as possible.
Continuing with these efforts, CLC distributes PCR and Extraction Instruments additional to their COVID-19 product offering. This includes the 3DMed ANDiS 380, which is a high-yield automated nucleic acid extraction system with a 96-well extractor. This instrument can run 96 extractions in 40 minutes and has an extremely high extraction efficiency, with a >95% recovery rate of magnetic beads.
CLC provides the Azure Cielo™ 6, a 96-Well Real-Time PCR System designed to be user-friendly with a large touch screen interface and software compatible with LIMS. The Azure Cielo™ 6 also contains optics and thermal blocks designed to deliver the same uniformity and reproducibility for high-throughput testing.
CLC also offers FDA Emergency Use Authorized Real-Time RT-PCR Test Kits. The QuantiVirus™ SARS-CoV-2 Test Kits from DiaCarta are based on real-time Reverse-Transcription Polymerase Chain Reaction (RT-PCR) technology, developed for specific detection of SARS-CoV-2 (COVID-19) viral RNA extracted from nasopharyngeal swabs, oropharyngeal, and sputum samples.
More on ncarol.com
Most notably, CLC offers the Point-of-Care/CLIA-Waived/Fingerstick Fastep® COVID-19 IgG/IgM Rapid Test Device by Assure Tech. This test has received FDA Emergency Use Authorization for use with fingerstick whole blood specimens at the point-of-care, i.e. in patient care settings operating under CLIA Certificate of Waiver such as doctor's offices, hospitals, urgent care centers, pharmacies, university health centers, and emergency rooms rather than having to be sent to a central lab. For all CLC COVID-19 products, please refer to www.carolinachemistries.com for instructions for use, fast facts for healthcare providers and patients, and EUA information.
All Emergency Use Authorized tests are authorized for the intended use provided by the FDA in the EUA; these EUAs can be found at www.carolinachemistries.com. These tests have not been FDA cleared or approved. Tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
More on ncarol.com
About Carolina Liquid Chemistries Corp.
Headquartered in Greensboro, NC, Carolina Liquid Chemistries Corp. (CLC) is an authorized manufacturer, re-packager, re-labeler and value-added distributor of chemistry systems and reagents, as well as COVID-19 testing supplies. CLC helps clinical laboratories of all sizes reduce chemistry analyzer and reagent costs, while also receiving accurate and timely results. The company has responded to the COVID-19 pandemic by bringing several PCR and antibody tests to market under the FDA's Emergency Use Authorization. For more information, visit carolinachemistries.com or email [email protected].
SOURCE Carolina Liquid Chemistries
Related Links
https://www.carolinachemistries.com/
Continuing with these efforts, CLC distributes PCR and Extraction Instruments additional to their COVID-19 product offering. This includes the 3DMed ANDiS 380, which is a high-yield automated nucleic acid extraction system with a 96-well extractor. This instrument can run 96 extractions in 40 minutes and has an extremely high extraction efficiency, with a >95% recovery rate of magnetic beads.
CLC provides the Azure Cielo™ 6, a 96-Well Real-Time PCR System designed to be user-friendly with a large touch screen interface and software compatible with LIMS. The Azure Cielo™ 6 also contains optics and thermal blocks designed to deliver the same uniformity and reproducibility for high-throughput testing.
CLC also offers FDA Emergency Use Authorized Real-Time RT-PCR Test Kits. The QuantiVirus™ SARS-CoV-2 Test Kits from DiaCarta are based on real-time Reverse-Transcription Polymerase Chain Reaction (RT-PCR) technology, developed for specific detection of SARS-CoV-2 (COVID-19) viral RNA extracted from nasopharyngeal swabs, oropharyngeal, and sputum samples.
More on ncarol.com
- Captain Notepad Expands Free Custom Design Services Across Full Product Line
- Lake Norman Philharmonic - Free Spring Concert
- Sycor Introduces Spring Release 2026 of Sycor.Rental with AI-Driven Innovations and Enhanced Service Processes
- YOKE Expands NIL Club Into Athlete-Led Commerce With Athlete Merch Launch
- Floor Kings Announces Official Launch of Premier Epoxy Flooring Services Across Arizona
Most notably, CLC offers the Point-of-Care/CLIA-Waived/Fingerstick Fastep® COVID-19 IgG/IgM Rapid Test Device by Assure Tech. This test has received FDA Emergency Use Authorization for use with fingerstick whole blood specimens at the point-of-care, i.e. in patient care settings operating under CLIA Certificate of Waiver such as doctor's offices, hospitals, urgent care centers, pharmacies, university health centers, and emergency rooms rather than having to be sent to a central lab. For all CLC COVID-19 products, please refer to www.carolinachemistries.com for instructions for use, fast facts for healthcare providers and patients, and EUA information.
All Emergency Use Authorized tests are authorized for the intended use provided by the FDA in the EUA; these EUAs can be found at www.carolinachemistries.com. These tests have not been FDA cleared or approved. Tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
More on ncarol.com
- STEM For Kids and Operation Xcel Partner to Drive Student Success Through Innovative STEM Pilot
- UK Buyers Purchase Luxury Home in Keene's Pointe, Windermere (Orlando, Florida)
- Instant IP Launches Rapid Takedown Service to Combat IP Theft, Deepfakes, and Copycat Websites
- Su Che Publishing Announces New Children's Book Celebrating Vaisakhi Festival
- Permian Museum Adds Photos of Fossils Discovered on a Meteorite
About Carolina Liquid Chemistries Corp.
Headquartered in Greensboro, NC, Carolina Liquid Chemistries Corp. (CLC) is an authorized manufacturer, re-packager, re-labeler and value-added distributor of chemistry systems and reagents, as well as COVID-19 testing supplies. CLC helps clinical laboratories of all sizes reduce chemistry analyzer and reagent costs, while also receiving accurate and timely results. The company has responded to the COVID-19 pandemic by bringing several PCR and antibody tests to market under the FDA's Emergency Use Authorization. For more information, visit carolinachemistries.com or email [email protected].
SOURCE Carolina Liquid Chemistries
Related Links
https://www.carolinachemistries.com/
0 Comments
Latest on ncarol.com
- As Global Tensions Rise, Demand Grows for Private Spaces to Process Thoughts and Speak Freely Online
- Martin Brossman Highlights Practical AI Strategies for Educators at Eastern NC Future Forum
- Cryptsoft demonstrates Hybrid-PQC Authentication Token use for quantum-safe systems and infrastructure
- Expert Law Attorneys' Top Law Firms to Know: March 2026
- Transform Your Home with G&R Landmark Renovations
- Green Office Partner Strengthens Global Operations with Mexico-Based DigitalVAAR Partnership
- P-Wave Classics Announces the Publication of The Female Quixote, Volume I, by Charlotte Lennox
- Everwild Music Festival Unveils 2026 Schedule: No Overlapping Sets, Longer Performances, and Epic Late-Night Sets!
- Riggo Production Studio Launches Monthly Content Package for Growing Brands
- Accelerating into Active Oil Production with over 100 Barrels per day now being produced as Dual-revenue engine begins Generating Cash Flow: $IBG
- Finland emerges as clear Eurovision 2026 favourite – analysis of 12 bookmakers by Vedonlyöntisivut
- Mac Mountain Selects netElastic vRouter for LightCraft Broadband-as-a-Service Platform
- 88% Revenue Growth; Charging Into the Future with Explosive Growth, Strategic EV Expansion and Infrastructure Dominance Signal a Breakout Opportunity
- Forge Resources Unlocks Major Gold-Copper System in Yukon as Drilling Success and Strategic Assets Fuel High-Impact Growth Story for: $FRGGF
- Game Day Private Jets Launches REVUP Platform to Transform Fan & Donor Travel Into a Revenue Engine for College Athletics
- Heritage at South Brunswick Team Celebrates Major Wins at NJBA Sales and Marketing Awards
- InterMountain Announces the Opening of TownePlace Suites Reno
- Home Builders Association of Durham, Orange & Chatham Counties Awards Local Scholarships
- New from Regal House Publishing, A Woman in Pink, devotion to an addict is a love story gone wrong
- MAG Magna Corp Targets Trillion-Dollar Opportunity by Tokenizing Rare Earth Assets Critical to AI, EVs, & Defense: MAG Magna Corp.: Stock Symbol: MGNC
